Postoperative Abemaciclib Significantly Improves Overall Survival: 7-Year monarchE Results
In this article
A long-awaited milestone in breast cancer treatment has arrived. Published on 17 October 2025 in Annals of Oncology and presented at the ESMO 2025 Congress, the monarchE trialshowed that two postoperative years of abemaciclib (Yulareb) + endocrine therapy (ET), compared with ET alone, significantly extended survival .
FDA Approvals: When and Based on Which Results?
12 October 2021 — The FDA approved abemaciclib + ET, based on interim monarchE analyses, for high-recurrence-risk (node-positive) ER+/HER2− early breast cancer in the adjuvant setting. At that time, Ki-67 ≥ 20% was required. This became the first CDK4/6 inhibitor approved in the adjuvant setting.
3 March 2023 — With subsequent monarchE data, the FDA expanded approval and removed the Ki-67 requirement. High risk is now defined by ≥4 pathological axillary lymph nodes or 1–3 nodes + grade 3 and/or tumor ≥5 cm .
Why Does It Matter?
Breast cancer is the most common cancer in women, with approximately two-thirds of cases hormone receptor-positive (ER+) and HER2-negative . Although generally slower-growing, recurrence risk persists for years. Long-term postoperative endocrine therapy (ET) has therefore been fundamental to extending life.
Yet over the past 20 years—despite advances with tamoxifen, aromatase inhibitors, and ovarian suppression—no new drug had improved postoperative overall survival (OS) . The monarchE trial became the first major step to change this.
The trial showed that, in patients with high-risk early breast cancer (such as node involvement or high-grade tumors), two years of abemaciclib + ET compared with ET alone reduced mortality risk by 15.8% and that the effect persisted for years after treatment ended .
Abemaciclib provides “silent” protection after surgery by suppressing microscopic cancer cells early that may remain after removal of the disease. This lasting effect is known scientifically as the “carry-over effect”, or lasting treatment effect —benefit continuing even after treatment stops.
In brief, monarchE is more than a drug trial; it is a new milestone in the evolution of breast cancer treatment. For the first time, an adjuvant CDK4/6 inhibitor has demonstrated longer survival, opening the way to more personalized, biologically targeted approaches.
How Was the Trial Conducted?
monarchE is a large trial involving more than 5,600 patients. All received standard hormone therapy (ET) after breast cancer surgery, while one group additionally took abemaciclib for 2 years .
- Who was included? ER+/HER2– breast cancer patients with involved lymph nodes or large/rapidly proliferating (high-grade) tumors.
- Follow-up: Up to 7 years. Disease-free survival, distant spread, and overall survival were measured.
Adjuvant trials assess whether microscopic cells remaining after surgery can be eliminated and recurrences prevented. This breast cancer subtype can return even years later.
📈 What Do the Results Show?
1️⃣ Overall Survival (OS)
Among women receiving Abemaciclib + ET, mortality risk fell by 15.8%. At 7 years, of every 100 patients, approximately 87 were alive, compared with 85with ET alone. The difference may initially look small, but in slow-growing cancers, even a 2-point difference represents hundreds of women's lives.
2️⃣ Preventing Recurrence (IDFS and DRFS)
Abemaciclib not only extends survival but also reduces the likelihood of recurrence. At 7 years, the proportion without recurrence reached %77.4(70.9% with ET alone).
The risk of spread to distant organs (such as bone, liver, or lung) also fell significantly. These differences represent more than numbers: preventing metastases over the long term .
3️⃣ Safety
During two years of treatment, diarrhea, fatigue, and mild reductions in white blood cells may occur, but can generally be controlled with dose adjustments. No persistent or new long-term side effects were reported.
What Do These Findings Mean?
Abemaciclib is opening a new era in breast cancer treatment: previously, no postoperative CDK4/6 drug had demonstrated longer survival .
The results show that intervening while disease is microscopic, before it spreads through the body, provides a lasting advantage . Scientists call this the “carry-over effect”—benefit persisting for years after treatment ends.
What Does This Mean for Patients?
- For whom? For hormone receptor-positive, HER2-negative breast cancer with involved lymph nodes or rapid proliferation (high grade).
- How is it taken? Orally 2 times a day, added to hormone therapy for 2 years.
- What is its purpose? To prevent cancer cells possibly remaining after surgery from multiplying again.
- How are side effects managed? Doctors may adjust the dose or briefly interrupt treatment. Most patients can continue.
- Why does follow-up matter? Regular blood counts and liver tests are required throughout treatment for both safety and efficacy.
DROZDOGAN Academy Commentary
ESMO 2025 marked one of the strongest turning points in the history of adjuvant CDK4/6 inhibitors. In the NATALEE trial's 5-year results, ribociclib (400 mg, 3 years) + aromatase inhibitor treatment, compared with hormone therapy alone, significantly improved invasive disease-free survival (iDFS) . Moreover, this difference persisted after treatment, even two years later —scientifically validating the “3 years of treatment, 5 years of benefit” paradigm.
Together, these data from monarchE and NATALEE emphasize that early-stage CDK4/6 inhibition provides long-term benefit by controlling micrometastatic disease . Abemaciclib and ribociclib thus symbolize the postoperative goal of lasting biological silence .
Alongside scientific success, important practical considerations remain. In Türkiye, cost, monitoring burden, and quality of life must be evaluated together through pharmacoeconomic analyses . These 2–3-year treatments require frequent outpatient visits, laboratory tests, and cardiac follow-up.
Survival gains must therefore be balanced against toxicity burden, adherence, and sustainable use of healthcare resources . Studies in Türkiye should account for socioeconomic conditions and potential genetic differences, drawing on patient-centered real-world data .
In conclusion, both abemaciclib and ribociclib represent a promising adjuvant future. Their true value will depend not only on clinical efficacy but also on balancing long-term quality of life, access, and health economics . The coming years will begin an era measuring not only their biological but also their social benefits .
📚 Reference
- Johnston SRD, et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO Congress 2025 – LBA13.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.